Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach - Wikidata - wikimedia - TriplyDB

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach

http://www.wikidata.org/entity/Q28742444

about

Which anticholinergic drug for overactive bladder symptoms in adults Diabetes insipidus as a rare cause of acute cognitive impairment in multiple sclerosis.CUA guideline on adult overactive bladder Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overac Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial How to define a refractory idiopathic overactive bladder?A current perspective on geriatric lower urinary tract dysfunction.A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care.Overactive bladder, differential diagnosis, and clinical utility of fesoterodine New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Overactive bladder - 18 years - Part II Knowledge and understanding of urinary incontinence: survey of family practitioners in northern Alberta.A phase II dose-ranging study of mirabegron in patients with overactive bladder Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.β3-receptor agonists for overactive bladder--new frontier or more of the same?Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics.New therapies in the treatment of overactive bladder.Management of OAB in those over age 65.Urinary incontinence in frail elderly persons: Report from the 5th International Consultation on Incontinence.The effects of antimuscarinic treatment on the cognition of spinal cord injured individuals with neurogenic lower urinary tract dysfunction: a prospective controlled before-and-after study.Management of female urinary incontinence: A survey of urogynaecologists' view on the NICE guideline.Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.Neurogenic lower urinary tract dysfunction: evaluation and management.Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy.Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis.Neurogenic bladder in patients with traumatic spinal cord injury: treatment and follow-up.Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.Drugs for the overactive bladder: are there differences in persistence and compliance?A proof-of-concept study: mirabegron, a new therapy for overactive bladder.Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.

P2860

Q24203880-5D1A6FCD-D1F3-4B29-A802-A78C8E5127CC Q30678682-8E1A70FD-B937-4013-95CC-3CC1EA29EAAB Q33665026-1EE7E39A-409B-492D-82AE-F15B25F6FC94 Q34088943-31980CE2-C3E8-4283-A505-D4E9A289CA15 Q34269392-AD8848A7-FF12-4AD0-9892-3A9BF12C0DAF Q34991783-568E4AED-8D3E-4BB0-9D20-55C185B7EACE Q35024928-DC73BC96-9BAC-410E-A205-0F2623A5C431 Q35348864-D6719FD8-DD3B-4691-B16C-10EC33AAC4F7 Q35548496-45E7D086-E6FC-4999-B3DD-36EA274146D8 Q36020033-43E7485E-83E7-4811-88E2-5A04A501392A Q36087246-AD9B0403-C599-4E1F-B469-0DF479E72C68 Q36223634-6205048F-635F-4150-9F62-FDFC5780A25F Q36429651-67ADD0A4-E5E0-4D82-869D-3278EA912A42 Q36789948-EEB64507-FDA1-42A8-BACC-D3DB4587D22F Q36912766-B65F3CE4-BF09-400C-B24E-363FEDCCF171 Q37008174-FF5E2AEB-9F3F-4A1A-8F5F-363386B92430 Q37100337-E2EB0C2B-5081-4BA6-99C2-D694430E2E4A Q37399563-40CBF271-07F6-4541-BA1D-71172D7A5987 Q37879017-5EBAD14C-2FEF-44D0-A6C9-7E66990B0044 Q38020185-770B5148-ECBD-4C3C-A9E2-3C5CAEA0FB01 Q38107167-5E0F7A77-3B52-405B-B029-A97DB127D0C0 Q38112554-6E4B69D5-E7BC-4F8B-B751-EB21DFACEE7F Q38124045-1434D16E-EC47-46C6-988B-000EBDCE82AE Q38127155-715D9B24-1CA8-45A2-9A64-71EF156AF973 Q38202094-164C9DBE-67D7-4925-BF53-C8EDA2730E98 Q38635232-0DEA9EA0-4D6D-409E-93CC-067F186413B7 Q38663256-4258CE04-E4A7-4B1B-A3A6-9484507E594C Q38765381-000CF75D-4400-4798-BCA0-A90E0983C61D Q38892831-A7579891-140F-431B-B584-98A6B2E20607 Q39020998-5382948B-A3C2-4E17-A947-95F6894E4058 Q39037307-C15F1BB3-16D1-4124-99B6-B974F2AA1D82 Q39342723-0F423C62-01F8-47F5-9692-8B433B757D59 Q39459240-84BBB900-45FA-40AF-B1FE-A36DBAC0ACF9 Q40210531-5FBAEEFC-55C1-4A10-9472-5366F9716D54 Q40936665-7FF3E9A4-E7EF-436E-AD9B-3F3A518B056F Q42332340-A06CFB7C-36FA-4B79-A5C6-998DA7B7C90C Q44526404-B44042C2-3E70-444E-83D7-8D0F750E8D82 Q53630970-8F3320F4-2FEB-472C-87C6-33BFE3990D58

P2860

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach

http://www.wikidata.org/entity/Q28742444

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Adverse event assessment of an ...... network meta-analytic approach

@ast

Adverse event assessment of an ...... network meta-analytic approach

@en

Adverse event assessment of an ...... network meta-analytic approach

@nl

type

label

Adverse event assessment of an ...... network meta-analytic approach

@ast

Adverse event assessment of an ...... network meta-analytic approach

@en

Adverse event assessment of an ...... network meta-analytic approach

@nl

prefLabel

Adverse event assessment of an ...... network meta-analytic approach

@ast

Adverse event assessment of an ...... network meta-analytic approach

@en

Adverse event assessment of an ...... network meta-analytic approach

@nl

P1433

Q28742444-CC7109AB-DC2B-42E3-B037-E0B40292FA62

P1476

Q28742444-34749EFD-FD78-4314-B575-52651689E1F4

P2093

Q28742444-1150E2E1-9325-4D69-B792-017303937FC7

Q28742444-23C089EF-0800-40D1-9897-EDFB090D33C2

Q28742444-39359DD1-F1BA-4FB0-9263-3900E9179EB4

Q28742444-481E4E3E-D4BD-4590-98AA-F23440D3E2E6

Q28742444-4B97AF15-BD0F-44F5-93F8-FD822152296F

Q28742444-4BC88785-5C2F-48FF-8773-EF684384B305

Q28742444-E1C53EDE-BC42-4CE6-ADC4-B80CFB21D204

P2860

Q28742444-03D813DD-F230-4C87-BB63-30BF10768821

Q28742444-074839F8-FFAB-4B6D-A201-96051BBB0C48

Q28742444-12E88519-15B5-479A-91D7-6EAA4CFE3965

Q28742444-15A670D4-B53E-4A77-A0B7-821BFBF2968F

Q28742444-17BC3BC8-8A18-4E25-9712-4AE0BCC3A128

Q28742444-1D10E048-BB04-4380-9674-80EAA0EE509D

Q28742444-2210C6DD-D4C5-4F60-B1C5-AC91FEB70992

Q28742444-27E60470-A442-45B1-BB8A-A0EAA5C1E00F

Q28742444-297FCD03-9D58-4982-9B4C-832E299BC64F

Q28742444-29BFB0BB-DDDA-4F07-8197-563766730A0C

P304

Q28742444-CF720D52-43FF-49A3-B9C3-27B3DA517635

P31

Q28742444-6888F6F4-4355-48F4-A517-2A70C3CD1A0B

Q28742444-c88739a5-ffe3-4641-9d4c-6eb5eb9a8b46

P3181

Q28742444-D96C1F76-EF42-4B12-8555-1961D3A39C5F

P356

Q28742444-236B18CC-90A5-48BC-B3B6-919DA0E871EF

P407

Q28742444-ACCFFC66-7232-4A26-A2A9-7AC18484A5EE

P433

Q28742444-67A616C3-0359-492C-B0A2-1E7C7FFB02D8

P478

Q28742444-B1A59ADD-A1F3-4945-9A3D-EE814BBAB522

P577

Q28742444-155F552F-BBEE-4AC8-B4F5-05B11C4B10BE

P5875

Q28742444-12FBD592-61FB-4103-BA99-DCB0B59EEE9C

P698

Q28742444-C2DE2B2E-CC96-4109-BF24-0C5DA8538DE6

P932

Q28742444-1CFF5862-08DA-4869-9685-E261DD2C4FE0

P3181

P356

JOURNAL.PONE.0016718

P1433

P1476

Adverse event assessment of an ...... network meta-analytic approach

@en

P2093

Alfons G H Kessels

http://www.w3.org/2001/XMLSchema#string

Christoph Minder

http://www.w3.org/2001/XMLSchema#string

David Löhrer

http://www.w3.org/2001/XMLSchema#string

Holger J Schünemann

http://www.w3.org/2001/XMLSchema#string

Lucas M Bachmann

http://www.w3.org/2001/XMLSchema#string

Martin Umbehr

http://www.w3.org/2001/XMLSchema#string

Thomas M Kessler

http://www.w3.org/2001/XMLSchema#string

P2860

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

Which anticholinergic drug for overactive bladder symptoms in adults

Grading quality of evidence and strength of recommendations

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.

Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head.

Drug-induced prolongation of the QT interval.

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Overactive bladder significantly affects quality of life.

P304

e16718

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1593457

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0016718

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50271753

http://www.w3.org/2001/XMLSchema#string

P698

21373193

http://www.w3.org/2001/XMLSchema#string

P932

3044140

http://www.w3.org/2001/XMLSchema#string